Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Other Working Capital Changes (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Other Working Capital Changes for 14 consecutive years, with -$319000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Working Capital Changes fell 234.03% to -$319000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$87000.0, a 31.5% increase, with the full-year FY2024 number at -$130000.0, down 11.11% from a year prior.
  • Other Working Capital Changes was -$319000.0 for Q3 2025 at Plus Therapeutics, down from $339000.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $1.4 million in Q3 2023 to a low of -$1.5 million in Q2 2023.
  • A 5-year average of -$16250.0 and a median of -$29500.0 in 2023 define the central range for Other Working Capital Changes.
  • Biggest YoY gain for Other Working Capital Changes was 5370.37% in 2023; the steepest drop was 484.68% in 2023.
  • Plus Therapeutics' Other Working Capital Changes stood at $170000.0 in 2021, then crashed by 116.47% to -$28000.0 in 2022, then dropped by 7.14% to -$30000.0 in 2023, then decreased by 10.0% to -$33000.0 in 2024, then tumbled by 866.67% to -$319000.0 in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Other Working Capital Changes are -$319000.0 (Q3 2025), $339000.0 (Q2 2025), and -$74000.0 (Q1 2025).